15911-30-5

Basic information

• Product Name: 5-Thiazolecarboxylic acid, 4-methyl-2-(4-nitrophenyl)-
• CAS NO: 15911-30-5
• Molecular Formula: C11H8N2O4S
• Molecular Weight: 264.262
• Mol File: 15911-30-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5-Thiazolecarboxylic acid, 4-methyl-2-(4-nitrophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Thiazolecarboxylic acid, 4-methyl-2-(4-nitrophenyl)-(15911-30-5)
• EPA Substance Registry System: 5-Thiazolecarboxylic acid, 4-methyl-2-(4-nitrophenyl)-(15911-30-5)

Safety Data

• Hazardous Substances Data: 15911-30-5(Hazardous Substances Data)

Upstream product

• 2227-79-4 benzenecarbothioamide 
• 53715-64-3 4-methyl-2-phenyl-thiazole-5-carboxylic acid ethyl ester 
• 26060-30-0 4-nitrothiobenzamide 
• 15911-31-6 ethyl 4-methyl-2-(4-nitrophenyl)-1,3-thiazole-5-carboxylate 
• 33763-20-1 4-methyl-2-(phenyl)-1,3-thiazol-5-carboxylic acid 

Downstream Products

• 1354948-47-2 C₂₃H₂₂N₄O₅S 
• 343322-08-7 2-methyl-2-[4-{[(4-methyl-2-[4-nitrophenyl]-1,3-thiazol-5-ylcarbonyl)amino]methyl}phenoxy]propionic acid ethyl ester 
• 343322-10-1 2-methyl-2-[4-{[(4-methyl-2-[4-aminophenyl]-1,3-thiazol-5-ylcarbonyl)amino]methyl}phenoxy]propionic acid ethyl ester 
• 16059-29-3 4-methyl-2-(4-nitro-phenyl)-thiazole-5-carbonyl chloride 
• 58765-95-0 5-bromo-4-methyl-2-(4-nitro-phenyl)-thiazole 
• 15911-28-1 2-diazo-1-[4-methyl-2-(4-nitro-phenyl)-thiazol-5-yl]-ethanone 
• 54000-90-7 2-chloro-1-[4-methyl-2-(4-nitro-phenyl)-thiazol-5-yl]-ethanone 
• 54001-08-0 1-[4-methyl-2-(4-nitro-phenyl)-thiazol-5-yl]-ethanone 

Relevant articles and documents

Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARα agonists. 1. Discovery of a novel series of potent HDLc raising agents

The peroxisome proliferator activated receptors PPARα, PPARγ, and PPARδ are ligand-activated transcription factors that play a key role in lipid homeostasis. The fibrates raise circulating levels of high-density lipoprotein cholesterol and lower levels of triglycerides in part through their activity as PPARα agonists; however, the low potency and restricted selectivity of the fibrates may limit their efficacy, and it would be desirable to develop more potent and selective PPARα agonists. Modification of the selective PPARδ agonist 1 (GW501516) so as to incorporate the 2-aryl-2-methylpropionic acid group of the fibrates led to a marked shift in potency and selectivity toward PPARα agonism. Optimization of the series gave 25a, which shows EC50 = 4 nM on PPARα and at least 500-fold selectivity versus PPARγ and PPARγ. Compound 25a (GW590735) has been progressed to clinical trials for the treatment of diseases of lipid imbalance.

2-arylthiazole derivatives and pharmaceutical composition thereof

Pharmaceutical compositions for treating gout or hyperuricemia and containing a new categorized compound, i.e. 2-arylthiazole derivatives, as an active ingredient, are provided. The 2-arylthiazole derivatives in the present invention are represented by the following formula (I): STR1 wherein Ar is an unsubstituted or substituted pyridyl, thienyl, furyl, naphthyl or phenyl group; X is a hydrogen atom, alkyl group or carboxyl group which may be protected, and Y is a hydrogen atom, alkyl group, or a hydroxyl or carbonyl group which may be protected. Furthermore, novel compounds included in the 2-arylthiazole derivatives and pharmaceutically acceptable salts thereof are provided.